Roopal Thakkar

8.4k total citations · 4 hit papers
142 papers, 5.3k citations indexed

About

Roopal Thakkar is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Roopal Thakkar has authored 142 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Genetics, 90 papers in Epidemiology and 34 papers in Surgery. Recurrent topics in Roopal Thakkar's work include Inflammatory Bowel Disease (111 papers), Microscopic Colitis (88 papers) and Health Systems, Economic Evaluations, Quality of Life (14 papers). Roopal Thakkar is often cited by papers focused on Inflammatory Bowel Disease (111 papers), Microscopic Colitis (88 papers) and Health Systems, Economic Evaluations, Quality of Life (14 papers). Roopal Thakkar collaborates with scholars based in United States, Germany and France. Roopal Thakkar's co-authors include William J. Sandborn, Andreas Lazar, Geert D’Haens, Walter Reinisch, Jean‐Frédéric Colombel, Anne Robinson, Douglas C. Wolf, Martina Kron, Gert Van Assche and Mari Nishizaka and has published in prestigious journals such as JAMA, Gastroenterology and Nature Reviews Drug Discovery.

In The Last Decade

Roopal Thakkar

124 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

2011 946 citations William J. Sandborn, Gert Van Assche et al. Gastroenterology profile →
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

2011 683 citations Walter Reinisch, William J. Sandborn et al. Gut profile →
Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure

2007 645 citations Alexandre Mebazaa, Markku S. Nieminen et al. profile →
Hyperaldosteronism Among Black and White Subjects With Resistant Hypertension

2002 548 citations Roopal Thakkar et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roopal Thakkar United States	29	3.1k	2.7k	1.5k	1.3k	646	142	5.3k
Rune Erichsen Denmark	32	1.2k 0.4×	1.1k 0.4×	1.6k 1.1×	446 0.3×	293 0.5×	154	4.3k
G Hellers Sweden	34	3.5k 1.2×	2.9k 1.1×	2.6k 1.7×	152 0.1×	266 0.4×	68	5.4k
Georgios I. Papachristou United States	45	398 0.1×	1.2k 0.4×	6.2k 4.1×	478 0.4×	330 0.5×	232	7.2k
Bidan Huang United States	27	1.0k 0.3×	837 0.3×	1.1k 0.7×	564 0.4×	321 0.5×	63	2.7k
Jens Kjeldsen Denmark	35	1.7k 0.6×	1.3k 0.5×	1.3k 0.8×	97 0.1×	719 1.1×	161	3.6k
M G W Kettlewell United Kingdom	34	1.8k 0.6×	1.4k 0.5×	2.0k 1.3×	130 0.1×	171 0.3×	104	4.0k
Jean P. Molleston United States	37	359 0.1×	2.0k 0.7×	1.9k 1.2×	136 0.1×	282 0.4×	146	4.5k
Claudia Sommerer Germany	35	470 0.2×	728 0.3×	1.1k 0.7×	259 0.2×	400 0.6×	164	4.6k
Mauro Salizzoni Italy	43	169 0.1×	3.7k 1.3×	3.3k 2.2×	207 0.2×	183 0.3×	202	7.2k
P. G. Lankisch Germany	41	406 0.1×	1.3k 0.5×	6.4k 4.2×	122 0.1×	250 0.4×	146	7.5k

Countries citing papers authored by Roopal Thakkar

Since Specialization

Citations

This map shows the geographic impact of Roopal Thakkar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roopal Thakkar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roopal Thakkar more than expected).

Fields of papers citing papers by Roopal Thakkar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roopal Thakkar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roopal Thakkar. The network helps show where Roopal Thakkar may publish in the future.

Co-authorship network of co-authors of Roopal Thakkar

This figure shows the co-authorship network connecting the top 25 collaborators of Roopal Thakkar. A scholar is included among the top collaborators of Roopal Thakkar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roopal Thakkar. Roopal Thakkar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Suzuki, Yasuo, Satoshi Motoya, Hiroyuki Hanai, et al.. (2017). Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis. Journal of Gastroenterology. 52(9). 1031–1040. 8 indexed citations

Colombel, J F, Bindia Jharap, William J. Sandborn, et al.. (2016). Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. Alimentary Pharmacology & Therapeutics. 45(1). 50–62. 33 indexed citations

Guandalini, Stefano, et al.. (2016). Direct Costs in Patients with Celiac Disease in the USA: A Retrospective Claims Analysis. Digestive Diseases and Sciences. 61(10). 2823–2830. 18 indexed citations

Rutgeerts, Paul, Walter Reinisch, Jean‐Frédéric Colombel, et al.. (2015). Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointestinal Endoscopy. 83(1). 188–197.e3. 22 indexed citations

Colombel, Jean–Frédéric, William J. Sandborn, Subrata Ghosh, et al.. (2014). Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3. The American Journal of Gastroenterology. 109(11). 1771–1780. 124 indexed citations

Suzuki, Yasuo, Satoshi Motoya, Hiroyuki Hanai, et al.. (2013). Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. Journal of Gastroenterology. 49(2). 283–294. 133 indexed citations

Osterman, Mark T., William J. Sandborn, Jean–Frédéric Colombel, et al.. (2013). Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease. Gastroenterology. 146(4). 941–949.e2. 129 indexed citations

Reinisch, Walter, William J. Sandborn, Remo Panaccione, et al.. (2013). 52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants. Inflammatory Bowel Diseases. 19(8). 1700–1709. 85 indexed citations

Packer, Milton, Wilson S. Colucci, Lloyd D. Fisher, et al.. (2013). Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure. JACC Heart Failure. 1(2). 103–111. 285 indexed citations

10.

Sandborn, William J., J F Colombel, Geert D’Haens, et al.. (2013). Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn’s disease. Current Medical Research and Opinion. 29(5). 483–493. 21 indexed citations

11.

Sandborn, William J., et al.. (2012). PTU-110 Elevated C reactive protein in anti-TNF-naïve patients is associated with higher remission rates: Abstract PTU-110 Table 1. Gut. 61(Suppl 2). A229.2–A230. 2 indexed citations

12.

Sandborn, William J., et al.. (2012). PTU-108 Induction of remission with adalimumab in patients with moderate Crohn's disease: subanalysis of CLASSIC I: Abstract PTU-108 Table 1. Gut. 61(Suppl 2). A228.2–A229. 1 indexed citations

13.

Sandborn, William J., Gert Van Assche, Roopal Thakkar, et al.. (2012). PWE-253 Adalimumab improves health-related quality of life for 52 weeks in patients with ulcerative colitis: Abstract PWE-253 Table 1. Gut. 61(Suppl 2). A400.3–A401. 2 indexed citations

14.

Sandborn, W., J F Colombel, Kathleen G. Lomax, et al.. (2011). Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with crohn's disease: data from extend: Table 1. Gut. 60(Suppl 1). A136.2–A137. 10 indexed citations

15.

Reinisch, Walter, et al.. (2011). 52-Week clinical efficacy with adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants: Table 1. Gut. 60(Suppl 1). A139–A140. 9 indexed citations

16.

Loftus, Edward V., J. Chao, Mei Yang, et al.. (2011). Markov model projection of remission status for early versus delayed step-up adalimumab use in moderate to severe crohn's disease. Gut. 60(Suppl 1). A137–A137. 1 indexed citations

17.

Reinisch, Walter, William J. Sandborn, Daniël W. Hommes, et al.. (2011). Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 60(6). 780–787. 683 indexed citations breakdown →

18.

Mebazaa, Alexandre, Markku S. Nieminen, Gerasimos Filippatos, et al.. (2009). Levosimendan vs. Dobutamine: Outcomes for Acute Heart Failure Patients on β-Blockers in SURVIVE. European Journal of Heart Failure. 11(3). 304–311. 117 indexed citations

19.

Kawata, Ariane K., Dennis A. Revicki, Roopal Thakkar, et al.. (2009). Flushing ASsessment Tool (FAST©). Clinical Drug Investigation. 29(4). 215–229. 18 indexed citations

20.

Insull, William, Jan Basile, Anthony Vo, et al.. (2009). Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study. Journal of clinical lipidology. 3(2). 109–118. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact